Connect Sign In
ARUP profiles laboratorians to help celebrate the meaningful and important work medical laboratory scientists do each day to benefit patients.
ARUP CEO Sherrie L. Perkins, MD, PhD, is the featured guest on the newest episode of “U Rising,” a podcast that introduces listeners to “people who are helping the U along its upward trajectory.”
Just a few months into the COVID-19 pandemic, the healthcare market is flush with COVID-19 laboratory testing platforms. This increase can make it challenging to critically evaluate COVID-19 tests.
Since the start of the COVID-19 pandemic, the ID Division has followed well-established protocols for respiratory specimens.
The ACLA has asked the CDC to take immediate steps to educate healthcare providers and the public about the importance of prioritizing COVID-19 testing for those most in need, a plea ARUP endorses.
While most blood drives have been canceled, ARUP’s two blood donation centers have remained open. ARUP has seen donations increase as more people have sought ways to help.
As the state of Utah continues to expand testing to halt the spread of COVID-19, its two largest laboratory services providers are reaffirming their commitment to work together to meet testing needs.
Due to supply constraints in the face of extraordinary demand for COVID-19 testing, ARUP told its national clients it can no longer accept orders for its 2019 Novel Coronavirus SARS-CoV-2 by PCR test.
ARUP Laboratories today announced the launch of its new test for the novel coronavirus. ARUP will start COVID-19 testing on March 12, 2020.
Clinical laboratory leaders met with Vice President Mike Pence and members of the government’s Coronavirus Task Force to discuss issues related to COVID-19 testing and response.
AnalyticsDx™ Comprehensive is a new tool that arranges lab testing data into a visual dashboard that allows you to see your organization’s trends and provides customized recommendations.
ARUP Laboratories announced today that the Food and Drug Administration (FDA) has filed ARUP’s premarket approval application (PMA) for an AAV5 total antibody assay.
